Amicus Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Cranbury, NJ USA
Total Funding:$294.6M
Industry:Biotech
Founded:2002
Lead Investor(s):BofA Merrill Lynch
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Amicus Therapeutics's estimated revenue is currently $91.2M per year.
  • Amicus Therapeutics received $300.0M in venture funding in February 2018.
  • Amicus Therapeutics's estimated revenue per employee is $164702
  • Amicus Therapeutics's total funding is $294.6M.

Employee Data

  • Amicus Therapeutics has 554 Employees.
  • Amicus Therapeutics grew their employee count by 17% last year.
  • Amicus Therapeutics currently has 66 job openings.

Executive Contacts

NameTitle
Anthony SilenoVice President Clinical Operations & Translational Sciences
Bradley CampbellPresident & Chief Operating Officer
Enrique DiloneSVP, Technical Operations
Hung DoSr Director of Discovery biology
Jayne GershkowitzChief Patient Advocate
Joseph BerrySr Director Supply Chain
Dennis KnoxAssociate Director Quality Assurance
Matthew NelsonRegional Director, MSLs-East
Arun GaurExecutive Director and Head, Global Quality Control, Small Molecules, Biologics and Gene Therapy
Tracey Mannion GrahamSr. Medical Science Liaison, Associate Director, Rare Disease

What Is Amicus Therapeutics?

Amicus Therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. We have a unique set of platform technologies and medicines in development for patients living with the Lysosomal Storage Disorders Fabry disease and Pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our Amicus footprint spans 27 countries including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Canada, Germany, Italy, The Netherlands, Spain, France, and Japan. More information about Amicus and our career opportunities can be found at www.amicusrx.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

554

Number of Employees

$91.2M

Revenue (est)

66

Current Jobs

17%

Employee Growth %

$294.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
GENEWIZ
$75.8M5283%
Hitachi Chemica...
$29.9M24213%
Canfield Scient...
$29.3M202-32%
Thomas Scientif...
$21.5M18123%
L Oreal USA
N/A0N/A
Insmed Incorpor...
$97.3M42111%
Amicus Therapeu...
$91.2M55417%$294.6M
Celularity
N/A14916%$367.7M
Legend Biotech ...
$12.8M98227%
ADMA Biologics
$23.1M16610%

Amicus Therapeutics News

09/03/2019 - Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019

CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) today announced upcoming presentations at the ...

09/08/2019 - Amicus Therapeutics, Inc. (FOLD) – Much Better Than You Think

WHITMAN BURKE W, Director, added 4,945 shares of Amicus Therapeutics, Inc. (FOLD) to its portfolio at the rate of $10.07 per share valuing ...

09/03/2019 - A Popularity Reversal Is Needed For Amicus Therapeutics, Inc. (FOLD)

Amicus Therapeutics, Inc., (FOLD) shares ended September 05, 2019 trading at $9.53 which saw uptrend of -0.52% since the beginning of ...

Amicus Therapeutics Funding

DateAmountRoundLead InvestorsReference
2003-10-01$1.0MPrivate OfferingArticle
2004-05-13$31.0MBCanaan PartnersArticle
2005-09-09$55.0MCQuaker BioVenturesArticle
2006-05-19$86.2MUndisclosedMorgan Stanley, Goldman Sachs and CoArticle
2006-09-15$60.0MDNew Enterprise AssociatesArticle
2006-09-28$60.0MUndisclosedArticle
2007-04-03$86.2MUndisclosedArticle
2007-06-04$60.0MUndisclosedMorgan Stanley and Co Incorpor, Merrill Lynch and CoArticle
2010-02-26$18.5MUndisclosedLeerink Swann LLCArticle
2012-03-05$54.0MUndisclosedLeerink Swann LLC , Cowen and Company LLCArticle
2013-12-05$15.0MUndisclosedArticle
2014-01-02$25.0MUndisclosedMidCap Financial, LLCArticle
2014-11-21$90.0MUndisclosedMultipleArticle
2014-11-25$103.5MUndisclosedJ.P. Morgan Securities LLCArticle
2015-06-15$258.8MUndisclosedJ.P. Morgan Securities LLCArticle
2017-07-14$258.8MUndisclosedJ.P. Morgan Securities LLCArticle
2018-02-19$300.0MUndisclosedBofA Merrill LynchArticle

Amicus Therapeutics Executive Hires

DateNameTitleReference
2005-01-25John F. CrowleyChairman / CEOArticle
2006-01-09David J. LockhartChf Scientific OffArticle
2006-04-03Donald J. HaydenChairmanArticle
2006-10-03James E. DentzerCFOArticle
2007-03-06John F. CrowleyPresident/CEOArticle
2010-02-08John CrowleyCEO/ChairmanArticle
2011-04-19John F. CrowleyChairmanArticle
2012-01-24Bradley L. CampbellChief Business OfficerArticle
2012-04-17William D. BairdCFOArticle
2015-04-28David AllsopSVP InternationalArticle
2016-07-13Andrew MulbergVP Regulatory StrategyArticle
2017-10-09Michael DiemSVP Business Corporate DevelopmentArticle

Amicus Therapeutics New Location/Offices

DateLocationReference
2008-09-16San Diego, CAArticle

Amicus Therapeutics Acquisitions

DateCompany NameAmountNotesReference
2013-11-21Callidus Biopharma, Inc.Cash Deal - Not CompleteArticle

Amicus Therapeutics Hiring Plans

DateNumber of EmployeesLocationReference
2019-02-27200PhiladelphiaArticle

Amicus Therapeutics Staff Cuts

DateNumber of EmployeesLocationReference
2013-11-2291 Employees or 14% WorkforceArticle